Tyenne (tocilizumab-aazg subcutaneous injection) — Medica

Initial criteria

• age > 18 years
• patient has tried or is currently taking a systemic corticosteroid, or systemic corticosteroids are contraindicated
• prescribed by or in consultation with a rheumatologist

Reauthorization criteria

• patient has been established on therapy for at least 6 months
• patient experienced a beneficial clinical response from baseline (objective measure or improvement in symptoms)

Approval duration

initial 6 months; reauthorization 1 year